Associations of plasma-soluble fas ligand with aging and age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1345-1349

  Jiang, Shunai ^a,b   Moriarty Craige, Siobhan E ^a   Li, Chun ^c   Lynn, Michael J ^d   Cai, Jiyang ^e   Jones, Dean P ^a   Sternberg, Paul ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ADULT; AGED; AGING; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA MACULA AGE RELATED DEGENERATION; SEX DIFFERENCE; BLOOD; MIDDLE AGED; PHYSIOLOGY; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; AGING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED;

EID: 45549104910     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0308     Document Type: Article

References (43)

1. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598-614.
2. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case-control study in the age-related eye disease study. Age-Related Eye Disease Study Report number 3. Ophthalmology. 2000;107:2224-2232.
3. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. Mech Ageing Dev. 2004;125:811-826.
4. Kalayoglu MV, Galvan C, Mahdi OS, Byrne GI, Mansour S. Serological association between Chlamydia pneumoniae infection and age-related macular degeneration. Arch Ophthalmol. 2003;121: 478-482.
5. Miller DM, Espenosa-Heidmann DG, Legra JL, et al. The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am J Ophthalmol. 2004;138:323-328.
6. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308: 385-389.
7. Haines JL, Hauser MA, Schmidt S. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419 - 421.
8. Edwards AO, Ritter RIII, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
9. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458-462.
10. Seddon JM, George S, Rosner B, Klein ML. Links CFH gene variant Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered. 2006;61:157-165.
11. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704-710.
12. Yu BP, Chung HY. Adaptive mechanisms to oxidative stress during aging. Mech Ageing Dev. 2006;127:436- 443.
13. Joseph JA, Shukitt-Hale B, Casadesus G, Fisher D. Oxidative stress and inflammation in brain aging: nutritional consideration. Neuro-chem Res. 2005;30:927-935.
14. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233-243.
15. SudaT, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med. 1994;179:873-879.
16. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
17. Fas SC, Fritzsching B, Suri-Payer, E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Auto-immun. 2006;9:1-17.
18. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228-238.
19. Wajant H. CD95L/FasL and TRAIL in tumor surveillance and cancer therapy. Cancer Treat Res. 2006;130:141-165.
20. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med. 1995;181:2029 -2036.
21. Sugimoto M, Shimaoka M, Hosotsubo K, et al. Up-regulation of Fas ligand (FasL) mRNA expression in peripheral blood mononuclear cells (PBMC) after major surgery. Clin Exp Immunol. 1998;112: 120-125.
22. Hosaka N, Oyaizu N, Kaplan MH, Yagita H, Pahwa S. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. J Infect Dis. 1998;178:1030-1039.
23. Bruserud O, Ulvestad E. Soluble Fas/Apo-1(CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells: contributions from local release and variations in systemic levels. Cancer Immunol Immunother. 2000;49:377-387.
24. Das H, Imoto S, Murayama T, et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol. 1999;104:795-800.
25. Hashimoto H, Tanaka M, Suda T, et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1998;41:657-662.
26. Okura T, Watanabe S, Jiang Y, et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens. 2002;20:895-898.
27. Lapinski TW. The concentration of sFasL, ICE and IL-1 beta in the serum and the liver tissue of chromic HCV infected patients. Hepatogastroenterology. 2005;52:1479-1483.
28. Suzuki M, Aoshiba J, Nagai A. Oxidative stress increases Fas ligand expression in endothelial cells. JInflamm (Lond). 2006;3:11.
29. Dockrell DH. The multiple roles of Fas ligand in the pathogenesis of infectious diseases. Clin Microbiol Infect. 2003;9:766-779.
30. Baran J, Weglarczyk K, Mysiak M, et al. Fas (CD95)-Fas ligand interactions are responsible for monocyte apoptosis occurring as aresult of phagocytosis and killing of Staphylococcus aureus. Infect Immun. 2001;69:1287-1297.
31. Serrao KL, Fortenberry JD, Owens ML, Harris FL, Brown LA. Neu-trophils induce apoptosis of lung epithelial cells via release of soluble Fas ligand. Am J Physiol. 2001;280:L298-L305.
32. Aggarwal S, Gupta S. Increased apoptosis of T cell subsets in aging human: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J Immunol. 1998;160:1627-1637.
33. Phelouzat MA, Lagorge T, Arbogast A, Quadri RA, Boutet S, Proust JJ. Susceptibility of apoptosis of T lymphocytes from elderly human is associated with increased in vivo expression of functional Fas receptors. Mech Ageing Dev. 1997;96:35-46.
34. Jiang S, Wu MW, Sternberg P, Jones DP. Fas mediates apoptosis and oxidant-induced cell death in cultured hRPE cells. Invest Ophthalmol Vis Sci. 2000;41:645-655.
35. Lambooij AC, Kliffen M, Mooy CM, Kuijpers RW. Role of Fas-ligand in age-related maculopathy not established. Am J Ophthalmol. 2001;132:437-439.
36. Gaillard RC, Spinedi E. Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine-immunologicalsexual dimorphism. Domest Anim Endocrinol. 1998;15:345-352.
37. McGwin G, Hall TA, Xie A, Owsley C. The relation between C reactive protein and age-related macular degeneration in the cardiovascular health study. Br J Ophthalmol. 2005;89:1166-1170.
38. Dasch B, Fuhs A, Behrens T, et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol. 2005;123:1501-1506.
39. Klein R, Klein B, Knudtson MD, Wong TY, Shankar A, Tsai MY. Systemic markers of inflammation, endothelial dysfunction and age-related maculopathy. Am J Ophthalmol. 2005;140:35-44.
40. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005;123:774-782.
41. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999; 5:292-297.
42. Semkova I, Fauser S, Lappas A, et al. Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovasculariza-tion. FASEB J. 2006;20:E950-E962.
43. Neff TA, GuoR, Neff SB, et al. Relationship of acute lung inflammatory injury to Fas/FasL system. Am J Pathol. 2005;166:685-694.